Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 59-7939 dose-finding study in acute symptomatic proximal deep vein thrombosis
ACTRN12605000601639Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rivaroxaban in deep vein thrombosis (DVT) (4 arms), sponsored by Bayer. Primary endpoint: Primary efficacy response by complete compression ultrasound. Started Mar 2004; status: completed.
02
Drugs
rivaroxaban
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on ACTRN12605000601639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000601639.